T he anesthesiologist has a central role in the management of acute postoperative pain, and effective management has been clearly demonstrated to improve clinical outcomes (1, 2) . Acute pain can rapidly evolve into chronic pain, and the two should not be viewed as separate entities (3) . Failure to achieve effective analgesia is a major predictive factor for the conversion of acute postoperative pain to chronic pain after several different types of surgery (4) .
Traditionally, opioids and local anesthetics have been the pharmacological foundation for postoperative pain management; however, optimization has been difficult because of anxieties regarding deleterious side effects. Opioids may cause respiratory depression, oversedation, and prolongation of postoperative ileus. Regional anesthetic techniques are limited by the requirement for special monitoring and the irreversibility of neuronal blockade once it is instituted.
The effectiveness of nonsteroidal antiinflammatory drugs (NSAIDs) in alleviating pain and reducing requirements for opioids in the postoperative period has been well documented (5-7), but concerns regarding gastropathy, renal dysfunction, and hemostatic defects have limited their use. There is further anxiety because fasting and the frequent prevalence of hypovolemia in the postoperative period may potentiate gastric and renal side effects.
Do anesthesiologists underuse NSAIDs as perioperative analgesics because of exaggerated anxieties regarding side effects and inadequate information regarding mode of action? This review article describes prostaglandin (PG) biosynthesis and the central role of cyclooxygenase (COX) expression in pain perception, and then it focuses on the potential side effects of COX inhibition.
Goals of Postoperative Analgesia
The goal of postoperative pain relief is to achieve optimal analgesia, facilitating a speedy return to normal physiological organ function with minimal side effects. Anesthesiologists must also try to reduce the incidence of chronic pain after surgery by effective treatment of acute postoperative pain. Minimization of opioid and local anesthetic side effects is a major consideration, and here NSAIDs have great potential. This process begins at the preoperative assessment, when the anesthesiologist must identify patients at increased risk of NSAID-induced complications. Although renal failure, allergy, and late pregnancy are absolute contraindications, a history of peptic ulcer disease, congestive cardiac failure, or cirrhosis, previous thrombosis, and concomitant corticosteroid therapy require further consideration before being classed as contraindications. A history of NSAID consumption for other conditions, such as arthritis, is reassuring, and a normal creatinine clearance will allay fears regarding postoperative renal failure.
PG Biosynthesis
In 1971, Vane (8) demonstrated that aspirin exerted its effects by inhibiting PG synthesis via inhibition of the enzyme COX. In 1991 the DNA sequence in human tissue for COX-1 was identified and, for COX-2, in 1992 (9,10). The two different isoforms are now called COX-1 and COX-2 (11).
Arachidonic acid is released from cell membrane phospholipid by the activity of phospholipase A 2 (PLA 2 ). PLA 2 is essential for PG synthesis, and a synchronous regulation of PLA 2 and COX has been demonstrated (12, 13) . The enzymatic activity of COX on arachidonic acid forms PGH 2 . Newly generated PGH 2 is then converted to PGD 2 , PGE 2 , and PGF 2␣ , prostacyclin (PGI 2 ), and thromboxane A 2 (TXA 2 ) by tissue-specific isomerases (11, 14) . All prostanoid synthesis is dependent on the action of COX on arachidonic acid, although the effect at the cellular level is cell specific. Endothelial cells synthesize mainly PGI 2 , which inhibits platelet aggregation, and platelets synthesize mainly TXA 2 , which has a proaggregational effect.
Recent work on rat tissue has also demonstrated different levels of expression of COX-1 and COX-2 messenger RNA (mRNA) in different organs. COX-1 mRNA was expressed in the liver, lung, and kidney, but not the heart, whereas COX-2 mRNA was expressed in the lung, heart, and kidney, but not the liver. This suggests that COX-1 and COX-2 have a regulatory physiological role that is organ specific. This may also indicate that certain organs will be more sensitive to COX inhibition than others (15) .
Surgical tissue trauma results in the release of a vast number of inflammatory mediators, including prostanoids. These mediators affect nociceptors, altering their firing threshold and sometimes causing direct stimulation (16) . COX-2 plays a key role in the central neurological response to inflammation. Immunoreactivity studies have demonstrated the presence of COX-2 in the superficial dorsal horn of the spinal cord (17, 18) , and PG receptors are found in dorsal root ganglia (19, 20) . It is at this level that the afferent sensory nerve axons enter the spinal cord and spinal nociceptive processing begins.
Central neurons generate both PGE 2 and PGI 2 in response to peripheral injury (21) , and intrathecal application of PGs induces pain behavioral responses (22, 23) . In a rat model, peripheral injury has resulted in COX-2 induction in the dorsal root neurons (21,24 -27) . Moreover, intrathecal COX inhibition has been demonstrated to reduce hyperalgesic responses to thermal injury in rats (28) . COX-1 and -2 are found in brain tissue, with COX-2 mRNA being demonstrated in the resting condition (29) . Electroconvulsive seizures induce COX-2 mRNA in rat brain, and this was found to be N-methyl-d-aspartate (NMDA) dependent, because the glutamate antagonist MK-801 abolished this response. COX-2 was also colocalized with glutamate in the dendrites of excitatory neurons (30) . NMDA receptor activation results in increased prostanoid synthesis (31) .
Neuronal depolarization is mediated by the excitatory amino acids glutamate and aspartate. These excitatory amino acids are present in many types of sensory neurons and exert their effects initially via ␣-amino-3-hydroxy-5-methyl isoxazolepropionic acid (AMPA) and kainate channels (32) . Excitatory amino acid activation of AMPA and kainate channels leads to activation of NMDA receptors, with resultant long-lasting partial depolarization; subsequent low-intensity stimuli, which previously were unable to generate an action potential, can then do so (33) . The activation of NMDA receptors is crucial for both acute pain perception and for central sensitization and windup to occur, potentially leading to chronic pain (34, 35) . Spinal NMDA activation causes acute mechanical nociception (through activation of COX-2 enzymes) and hyperalgesia (as a result of peripheral inflammation via upregulation of COX-2) (36). NMDA receptors have also been linked to COX-2 expression in a focal ischemia model, because the induction of COX-2 by ischemia is inhibited by an NMDA antagonist (37) . As with NMDA receptors, AMPA activation seen after global ischemia results in prolonged neuronal COX-2 expression (38) . The effects of NMDA and AMPA activation may be COX-2 dependent, because intrathecal injection of a COX-2 inhibitor inhibits the development of hyperalgesia induced by intrathecal injection of either NMDA or AMPA in a dose-dependent manner (39) . Thus, both AMPA and NMDA receptor activation are linked to COX-2 expression with resultant nociception (Fig. 1 ).
There is a distinct neurochemical response in acute and persistent pain. It is interesting to note that rat spinal cord sections from an adjuvant-induced arthritis model have demonstrated the induction of COX-2 at 22 days (40) . This is further evidence in support of the concept that the neurochemistry of the central spinal cord is altered in a specific fashion after an insult and that this effect may be prolonged (41, 42) . Thus, COX-2 expression induced by surgery may last longer than previously thought, and this raises the possibility of persistent COX-2 expression being a possible factor in the etiology of chronic pain after surgery.
Gastrointestinal Effects of COX
Clinically the most common side effects of NSAIDs are seen in the gastrointestinal system (43, 44) . The risk of NSAID-induced peptic ulcer complications results in approximately 1.25 additional hospitalizations per 100 patient-years on average. However, this may be affected by the presence of Helicobacter pylori and varies among different NSAIDs and dose regimens. Smalldose ibuprofen has been reported to cause fewer gastrointestinal complications than other NSAIDs. The risk of gastropathy is increased in patients who are elderly, have a history of peptic ulcer disease, or take concomitant corticosteroids or anticoagulants (45) .
There has been great interest in the cytoprotective role of PGs in the gastrointestinal system. In particular, PGE 2 and PGI 2 have been shown to increase mucous production and inhibit acid secretion in the stomach (46) . The healing of peptic ulcers is enhanced by COX-2-dependent PG synthesis (47) (48) (49) . Thus, it would seem that inhibition of PG synthesis by NSAIDs might provide a possible explanation for NSAID-induced peptic ulceration. It has been postulated that NSAID inhibition of COX-1 biosynthesis in the stomach is the key factor responsible for gastric erosion formation (50) . However, it has been demonstrated, in mice with a disrupted COX-1 gene, that the associated gastric PG synthesis reduction was not associated with gastric damage (51).
H. pylori infection in the stomach is associated with peptic ulcer disease, and it is interesting that even in the presence of H. pylori colonization, COX-2-dependent PG synthesis is present and may be protective (52) .
The use of selective COX-2 inhibitors in patients with osteoarthritis and rheumatoid arthritis has resulted in less gastric erosion than that seen when using earlier NSAIDs at dosages that have an antiinflammatory effect (53, 54) . These observations again support the hypothesis that it is COX-1 inhibition that leads to gastric erosion. However, recent evidence suggests that selectively inhibiting either COX-1 or COX-2 in isolation does not cause gastric erosion. Inhibition of both isoforms is to some extent required for gastric mucosal damage to occur (55) . The mechanism of NSAID-induced gastric mucosal ulceration is unclear, but it probably involves an NSAID-induced adherence of leukocytes to the vascular endothelium in the gastric microcirculation (56) in combination with a reduction in gastric blood flow (57) .
There has always been a concern that patients may be exposed to an increased risk of gastrointestinal and renal side effects from the use of NSAIDs for postoperative analgesia, because of postoperative fasting and the relatively frequent incidence of hypovolemia after major surgery. However, the newer NSAIDs have a greater COX-2 inhibitory effect, and although there are still some COX-1 inhibitory effects, there is growing clinical evidence of the superior tolerability of the more selective COX-2 inhibitors, with the Vioxx Gastrointestinal Outcome Research Group study demonstrating a 60% reduction in perforation, obstruction, and bleeding (58 -64).
Renal Effects of COX
Renal complications of NSAID use include acute renal failure, hyperkalemia, water and sodium retention, nephrotic syndrome, and interstitial nephritis (65, 66) . It is interesting to note that in the United States, prescription NSAID use results in 25 excess hospitalizations because of renal failure per 10,000 years of use in patients older than 65 yr. This suggests that NSAIDinduced complications in older people are uncommon (67) . However, it may not be possible to extrapolate these encouraging data to the perioperative period. COX-2 is constitutively expressed in the kidney (68) , and the role of PGs in renal homeostasis is complex. PGI 2 and PGE 2 are the major mediators, with PGI 2 found in the renal cortex and glomeruli and PGE 2 in the juxtamedullary glomeruli and medullary portion of the collecting ducts. They produce arteriolar dilation, increasing renal perfusion and sodium excretion, while reducing medullary tonicity and antidiuretic hormone effectiveness and stimulating renin secretion. PGI 2 attenuates podocyte constriction, thereby maintaining glomerular filtration rate (GFR) in the presence of angiotensin-2 and antidiuretic hormone. TXA 2 is found in the glomeruli, where it causes vasoconstriction and podocyte contraction and thus reduces glomerular filtration. PGF 2␣ enhances tubular sodium and water excretion (69) . Tubulo-glomerular feedback is an important mechanism of autoregulation for renal perfusion. The macula densa is the sensing part of this mechanism, and its activity requires a COX-2 pathway for signaling (70) . The effect of a selective COX-2 inhibitor (nimesulide) was compared with that of a nonselective inhibitor (meclofenamate) in dogs with normal and small sodium intake. The effects on renal hemodynamics, urinary sodium excretion, and fractional lithium excretion were quite different, suggesting that COX-2-derived PGs play an important role in sodium excretion and renal hemodynamics (71). Endogenous PGs have been demonstrated not to affect renal hemodynamics under the pressor effects of prolonged angiotensin-2 exposure. In fact, after significant renal injury, prolonged therapy with selective COX-2 inhibition decreased proteinuria and retarded further renal injury (72) . However, renal PGs do modulate the effects of subpressor angiotensin-2 levels by reducing vasoconstriction and enhancing tubular sodium absorption. This suggests that under the threat of hypoperfusion, endogenous renal PGs ensure that the renin-angiotensin system will work to maintain both renal and systemic perfusion. In patients with chronic renal failure, residual function is PG dependent, and here NSAIDs may cause rapid deterioration (69) .
Sodium retention and edema are found in 5% of the population taking NSAIDs (73). Hyperkalemia is noted in up to 46% of patients because of decreased renin secretion (74) .
Clinical trials have produced inconsistent results; one study demonstrated no GFR reduction in patients with chronic renal failure taking celecoxib or naproxen, whereas another demonstrated no difference in GFR reduction between patients taking rofecoxib or indomethacin (75) (76) (77) (78) . Patients with cardiac failure, cirrhosis, or hypertension have a predisposition to prerenal renal failure. The anesthesiologist should view these patients as being at increased risk for NSAID-induced renal failure. A recent study demonstrated that celecoxib caused less edema and destabilization of blood pressure control than rofecoxib in hypertensive patients and suggested that these patients should be monitored for cardiorenal events if they are prescribed selective COX-2 inhibitors (79). It is interesting that both celecoxib and rofecoxib have been reported to cause acute renal failure (80, 81) . The effect of diclofenac and ketorolac on perioperative renal function has been investigated in a rat model. The administration of the NSAIDs did not induce renal dysfunction. However, if combined with gentamicin, both NSAIDs produced marked deterioration in renal function, with associated pathologic changes in renal structure (82, 83 ). An interaction between ibuprofen and gentamicin resulting in renal failure has also been reported in humans (84) . This evidence suggests that the coadministration of aminoglycosides with NSAIDs in the perioperative period may be a significant risk factor for inducing renal failure.
PGs and the Cardiovascular System
Myocardial ischemia results in ischemic preconditioning, which protects myocardial cell function from further ischemic episodes. Evidence suggests that upregulation of nitric oxide is required for preconditioning (85) , and this is associated with a simultaneous induction of COX-2 (86). COX-2-mediated cardioprotection occurs in the later phases of preconditioning and is due to PGE 2 and PG⌱ 2 synthesis (87). These PGs attenuate myocardial stunning (88) and reduce infarct size (89) . The cytoprotective effects of PGE 2 and PG⌱ 2 are due to activation of adenosine triphosphate-sensitive potassium channels (89) and a reduction in myocardial neutrophil infiltration (90) . Although these animal data suggest that COX-2 inhibition may worsen myocardial performance in the presence of ischemia, there is now evidence that COX-2 inhibition reduces atherosclerosis. Atherosclerosis is now viewed as a chronic inflammatory condition (91) in which COX-2 is upregulated (92) . COX-2 inhibition markedly reduces neointimal formation in an animal model of atherosclerosis (93) .
There is concern regarding the effect of COX inhibition on renal artery tension. PGs have different effects on vascular smooth muscle; TXA 2 causes vasoconstriction and platelet aggregation (94), whereas PGI 2 has the opposite effect (95) . The in vitro vasoconstriction caused by angiotensin-2 in the human internal mammary artery is enhanced by, but not dependent on, eicosanoid biosynthesis produced from the COX pathway (96) . Therefore, vascular tension may be affected by COX inhibition, but neither isoform is predominant or is the sole factor affecting tension.
Postoperative Nausea and Vomiting
Work in conscious piglets has demonstrated that activation of the medullary vomiting center involves PGs. Lipopolysaccharide-induced emesis was abolished by COX inhibition by using both meloxicam and indomethacin, when these were administered before the lipopolysaccharide (97).
Hemostatic Complications
COX inhibition with NSAIDs may increase the risk of vascular thrombus formation by upsetting the balance of pro-and antiplatelet aggregation effects: TXA 2 synthesis is primarily a COX-1-induced effect, and PGI 2 is a COX-2 effect. Four patients with Raynaud's syndrome developed thrombotic complications after receiving COX-2 inhibition as part of their treatment (98) . This side effect is unreported with the nonselective COX inhibitors. Although platelet dysfunction occurs with COX-1 inhibition, there has been no prospective randomized control clinical trial demonstrating an increase in hemorrhage in patients who have received NSAIDs.
PG Interactions with Anesthetic Agents
Lipopolysaccharide administration enhances the hyperemic response. However, pretreatment with NS-398 attenuated these observed effects in rats when they were anesthetized with halothane, and the effects were abolished by aminoguanidine (an inducible nitric oxide synthase inhibitor) and dexamethasone. These results suggest that halothane-induced cerebrovascular hyperemia is achieved through a nitric oxideand COX-dependent pathway (99) .
PGs and Asthma
Aspirin and NSAIDs cause bronchoconstriction in approximately 10% of asthmatic patients, although it is interesting that they relieve it in approximately 0.3% of patients (100) . This illustrates the complexity of COX interaction in the lungs. Recent work has delineated possible explanations for aspirin-induced asthma (AIA), and these explanations will facilitate improved NSAID selection by anesthesiologists in this difficult population.
COX inhibition diverts arachidonic acid metabolites to the lipoxygenase pathway, with an associated reduction in PGE 2 synthesis and an increase in cysteinyl leukotrienes. Patients with AIA have increased cysteinyl leukotriene levels because of enzymatic overactivity, which can be fueled by more leukotrienes from COX inhibition (101) . There is growing evidence that AIA is due to COX-1 inhibitory effects and that selective COX-2 inhibitors are relatively safe to use in this population (102, 103) Preemptive Analgesia with NSAIDs
The concept of pain prevention, as opposed to pain treatment, is very attractive to anesthesiologists, and here NSAIDs have a role to play. Inhibition of COX expression prevents AMPA and NMDA receptor activation and ascending spinal "pain traffic." Although support for preemptive analgesia waned in the latter half of the 1990s because of conflicting trial results, renewed interest has developed as a greater understanding of the mechanism of central sensitization has been forthcoming. One of the major problems is agreement on the definition of preemptive analgesia. It may be defined as treatment that prevents the establishment of central sensitization caused by incisional and inflammatory injuries during both the surgical and initial postoperative periods (104) . Thus it is clear that treatment must be established long enough before surgery to have its full pharmacodynamic effect. Therefore, COX expression must be inhibited before surgery and during the initial postoperative period, because the response to surgery may last longer than originally thought. Work recently completed demonstrates a clear role for spinal COX-2 expression in postoperative nociception in humans (105) . There is growing support for the concept that NSAIDs' analgesic site of action is at the spinal level (106) . Therefore, the administered NSAID must have achieved COX inhibition spinally before the surgical stimulus. IV NSAID formulations are attractive in facilitating rapid plasma levels in the perioperative period, and this will minimize pharmacokinetic attenuation of the drug effect, which may occur with other routes of administration. Ketorolac and tenoxicam are available for IV administration, and preemptive analgesia has been demonstrated with both drugs (107, 108) . With preemptive analgesia now clearly defined, further research is eagerly awaited to decide whether this attractive analgesic modality should become part of everyday practice.
COX-1/COX-2 Selectivity of NSAIDs
Several techniques can be used to establish the selectivity ratios for different NSAIDs, including wholeblood assays for serum TXA 2 (COX-1) and plasma PGE 2 (COX-2), transfected cells, purified recombinant enzyme, and drug inhibition of human gastric PGs. There may be significant variations in selectivity, depending on the technique used, although drug inhibition of human gastric PGs may become the "gold standard" (43) .
Conclusions
The actual prevalence of side effects from prescription NSAIDs is small, and in the postoperative pain relief scenario they are excellent analgesics; standard doses of diclofenac give analgesia equivalent to 10 mg of IM morphine (109) . The analgesic efficacy of selective COX-2 inhibitors is equal to that of the nonselective NSAIDs, with significantly less potential for COX-1-induced complications (110) . There has been no prospective, randomized, controlled trial that demonstrates that patients who received NSAIDs have an increased risk of peptic ulceration, renal dysfunction, or hemostatic defect in the postoperative period compared with patients who did not receive NSAIDs. Despite the theoretical risk of drug interactions, there is a lack of supporting evidence for drug interactions involving selective COX-2 inhibitors (111). It is clear that COX-2 plays a central role in pain perception. The advent of NSAIDs that selectively inhibit COX-2 may minimize COX-1-dependent side effects while offering analgesia, a reduction in opioid requirements, and the potential to reduce the incidence of chronic pain after surgery and, possibly, also nausea and vomiting. Therefore, the development of these more selective COX-2 inhibitors, in conjunction with preoperative patient selection, opens the way for their safer use in the perioperative period. The one area of real concern continues to be renal function, and until further evidence appears, any preoperative evidence of renal dysfunction should preclude their use. However, because selective COX-2 inhibitors are well tolerated by patients with asthma, are associated with less gastric injury (at least acutely), and do not influence hemostasis (43), they may represent a safer alternative to nonselective NSAIDs in the treatment of postoperative pain.
